-

Signature Bank (SBNY) Class Action Alert: Investors with Large Losses Should Contact Robbins LLP for Information Regarding Their Rights

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Signature Bank (NASDAQ: SBNY) securities between March 2, 2023 and March 12, 2023, for violations of the Securities Exchange Act of 1934. Signature Bank purports to be a “New York-based full-service commercial bank with 40 private client offices located throughout the metropolitan New York area, as well as those in Connecticut, California, Nevada and North Carolina."

What Now: Similarly situated shareholders may be eligible to participate in the class action against Signature Bank. Shareholders who want to act as lead plaintiff for the class must file their papers by May 15, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Signature Bank (SBNY) Mislead Investors Regarding its Business Prospects

According to the complaint, on March 2 and 9, 2023, defendants touted the stability of its business model, diversified deposit mix, and high level of capital. These statements were false, however. On March 12, 2023, the New York Department of Financial Services ("DFS") took possession of Signature Bank and trading in the Company's shares were halted, essentially rendering the Company's shares illiquid and valueless given the bank's failure.

Defendants failed to disclose that Signature Bank did not have the strong fundamentals that it represented itself as having in the days immediately prior to its takeover, or otherwise took action that left it susceptible to a takeover by the DFS, and as a result, it became a target for regulatory action by the DFS.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Signature Bank settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SBNY

Release Summary
Signature Bank (SBNY) Mislead Investors Regarding its Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Snowflake Inc. Class Action Reminder - Robbins LLP Encourages SNOW Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Snowflake Inc. (NYSE: SNOW) Class A common stock between June 27, 2023 and February 28, 2024. Snowflake is a software company that provides cloud data storage that enables customers to consolidate data onto data-driven applications and share data for the purpose of running analytics and other processes. For more information, submit a form, ema...

Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.For more information, submit a...

uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period? September 24, 2025 – October 31, 2025What...
Back to Newsroom